Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. What Happened: The pharmaceutical giant is seeking to end a regulatory designation that has permitted cheaper, off-brand versions to thrive. Lawyers for Eli Lilly have notified healthcare providers that shortages of Mounjaro and Zepbound are effectively over, despite the FDA not yet confirming this status, reported The Washington Post. On Tuesday, Eli Lilly launched a discounted product, presenting it as a safer alternative to the off-brand medications…
